AR114216A1 - Composiciones oftálmicas de compuestos de bencimidazol para uso único diario - Google Patents

Composiciones oftálmicas de compuestos de bencimidazol para uso único diario

Info

Publication number
AR114216A1
AR114216A1 ARP190100094A ARP190100094A AR114216A1 AR 114216 A1 AR114216 A1 AR 114216A1 AR P190100094 A ARP190100094 A AR P190100094A AR P190100094 A ARP190100094 A AR P190100094A AR 114216 A1 AR114216 A1 AR 114216A1
Authority
AR
Argentina
Prior art keywords
daily use
single daily
ophthalmic compositions
benzimidazole compounds
bilastine
Prior art date
Application number
ARP190100094A
Other languages
English (en)
Spanish (es)
Inventor
Hernando Nieves Fernndez
Arce Arturo Zazpe
Poladura Pablo Morn
Gorostiza Ana Gonzalo
Herrero Gonzalo Hernndez
Tom Victoria Daz
Ferreiro Anxo Fernndez
Espinar Francisco Javier Otero
Cerdeiras Paloma Tato
Garca Tania Gonzlez
Original Assignee
Faes Farma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Faes Farma Sa filed Critical Faes Farma Sa
Publication of AR114216A1 publication Critical patent/AR114216A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ARP190100094A 2018-01-18 2019-01-17 Composiciones oftálmicas de compuestos de bencimidazol para uso único diario AR114216A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18382021 2018-01-18

Publications (1)

Publication Number Publication Date
AR114216A1 true AR114216A1 (es) 2020-08-05

Family

ID=61017875

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190100094A AR114216A1 (es) 2018-01-18 2019-01-17 Composiciones oftálmicas de compuestos de bencimidazol para uso único diario

Country Status (28)

Country Link
US (2) US20210128544A1 (cg-RX-API-DMAC7.html)
EP (2) EP3740191B1 (cg-RX-API-DMAC7.html)
JP (1) JP7309729B2 (cg-RX-API-DMAC7.html)
KR (1) KR102695627B1 (cg-RX-API-DMAC7.html)
CN (1) CN111727035B (cg-RX-API-DMAC7.html)
AR (1) AR114216A1 (cg-RX-API-DMAC7.html)
AU (1) AU2019209214B2 (cg-RX-API-DMAC7.html)
CA (1) CA3088740A1 (cg-RX-API-DMAC7.html)
CL (1) CL2020001895A1 (cg-RX-API-DMAC7.html)
CO (1) CO2020009992A2 (cg-RX-API-DMAC7.html)
CY (1) CY1124270T1 (cg-RX-API-DMAC7.html)
DK (1) DK3740191T3 (cg-RX-API-DMAC7.html)
EA (1) EA202091725A1 (cg-RX-API-DMAC7.html)
ES (1) ES2878107T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20211037T1 (cg-RX-API-DMAC7.html)
HU (1) HUE054594T2 (cg-RX-API-DMAC7.html)
LT (1) LT3740191T (cg-RX-API-DMAC7.html)
MA (1) MA51612B1 (cg-RX-API-DMAC7.html)
MX (1) MX2020007692A (cg-RX-API-DMAC7.html)
PL (1) PL3740191T3 (cg-RX-API-DMAC7.html)
PT (1) PT3740191T (cg-RX-API-DMAC7.html)
PY (1) PY1903392A (cg-RX-API-DMAC7.html)
SA (1) SA520412443B1 (cg-RX-API-DMAC7.html)
SI (1) SI3740191T1 (cg-RX-API-DMAC7.html)
TW (1) TWI833727B (cg-RX-API-DMAC7.html)
UY (1) UY38055A (cg-RX-API-DMAC7.html)
WO (1) WO2019141563A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202005077B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025508704A (ja) * 2022-02-17 2025-04-10 ファエス・ファルマ・ソシエダッド・アノニマ 1日1回非経口投与のためのビラスチン組成物
CN116211795B (zh) * 2022-12-26 2025-09-26 深圳市贝美药业有限公司 一种比拉斯汀口服液体制剂及其制备方法
CN115970066B (zh) * 2022-12-29 2024-09-27 成都爱睿康乐医疗器械有限公司 基于主客体相互作用的载药纳米凝胶生物润滑剂及其制备方法和应用
WO2024224326A1 (en) * 2023-04-27 2024-10-31 Leiutis Pharmaceuticals Llp Liquid parenteral formulations of bilastine
WO2024224308A1 (en) * 2023-04-27 2024-10-31 Leiutis Pharmaceuticals Llp Liquid parenteral formulations of bilastine free of cyclodextrins
WO2024256956A1 (en) * 2023-06-13 2024-12-19 Leiutis Pharmaceuticals Llp Stable formulations of bilastine for nasal and ophthalmic use

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1229075B (it) * 1985-04-05 1991-07-17 Fidia Farmaceutici Medicamenti per uso topico, ottenuti tramite l'impiego dell'acido ialuronico
ES2048109B1 (es) 1992-07-20 1994-12-16 Espanola Prod Quimicos Procedimiento de preparacion de nuevos derivados piperidicos del bencimidazol.
JP3527256B2 (ja) 1992-12-09 2004-05-17 ロート製薬株式会社 抗アレルギー点眼剤
TW401300B (en) * 1992-12-25 2000-08-11 Senju Pharma Co Antiallergic composition for ophthalmic or nasal use
ES2124167B1 (es) 1996-06-04 1999-09-16 Espanola Prod Quimicos Nuevos derivados del bencimidazol con actividad antihistaminica.
DE10161149B4 (de) * 2001-12-12 2007-03-08 Ursapharm Arzneimittel Gmbh & Co. Kg Verwendung von Heparin-haltigem Ophthalmikum
CA2484460C (en) 2002-04-19 2009-09-29 Faes Farma, S.A. Polymorph of 4-[2-[4-[1-(2-ethoxyethyl)-1h-benzimidazole-2-yl]-1-piperidinyl]ethyl]-.alpha..alpha. dimethyl-benzeneacetic acid
US20050239745A1 (en) * 2004-03-03 2005-10-27 Ophthalmic Research Associates, Inc. Novel topical ophthalmic formulations
US7247623B2 (en) 2005-08-19 2007-07-24 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with non-drying antihistamines
WO2007047253A2 (en) 2005-10-11 2007-04-26 Eastman Chemical Company Pharmaceutical formulations of cyclodextrins and antifungal azole compounds
UA94938C2 (ru) * 2006-03-31 2011-06-25 ВИСТЕКОН ФАРМАСЬЮТИКАЛС, ЭлЭлСи Офтальмическая композиция для лечения клинических симптомов глазной аллергии, которая содержит алкафтадин или его производное (варианты)
SG170044A1 (en) * 2006-03-31 2011-04-29 Vistakon Pharmaceuticals Llc Ocular allergy treatments
JP2010531898A (ja) 2007-06-28 2010-09-30 サイデックス・ファーマシューティカルズ・インコーポレイテッド 鼻および眼へのコルチコステロイド水溶液送達
JP2012520880A (ja) * 2009-03-17 2012-09-10 アーシエックス セラピューティックス, インコーポレイテッド ケトチフェンの眼科用製剤および使用方法
TWI544922B (zh) 2011-05-19 2016-08-11 愛爾康研究有限公司 高濃度歐羅派特錠(olopatadine)眼用組成物
CN103110575B (zh) * 2013-03-07 2014-11-05 宁夏康亚药业有限公司 一种美洛昔康滴眼液及其制备方法和应用
WO2014150899A1 (en) * 2013-03-15 2014-09-25 Chapin Matthew J Topical ophthalmic formulations for treating migraine
CN103784462A (zh) * 2014-02-25 2014-05-14 宋俊智 包含比拉斯汀及甾族化合物的药物制剂
EP3040334A1 (en) 2014-12-29 2016-07-06 Faes Farma, S.A. New benzimidazole derivatives as antihistamine agents

Also Published As

Publication number Publication date
ZA202005077B (en) 2024-12-18
CA3088740A1 (en) 2019-07-25
EP3740191B1 (en) 2021-04-28
HRP20211037T1 (hr) 2021-10-01
KR102695627B1 (ko) 2024-08-16
AU2019209214A1 (en) 2020-08-13
DK3740191T3 (da) 2021-06-07
PL3740191T3 (pl) 2021-11-29
CN111727035B (zh) 2024-05-28
BR112020014265A2 (pt) 2020-12-08
CY1124270T1 (el) 2022-07-22
MA51612A (fr) 2020-11-25
AU2019209214B2 (en) 2023-11-23
UY38055A (es) 2019-08-30
KR20200111727A (ko) 2020-09-29
PT3740191T (pt) 2021-07-09
MA51612B1 (fr) 2021-06-30
ES2878107T3 (es) 2021-11-18
MX2020007692A (es) 2020-09-14
CO2020009992A2 (es) 2021-01-18
HUE054594T2 (hu) 2021-09-28
WO2019141563A1 (en) 2019-07-25
PY1903392A (es) 2019-08-01
JP7309729B2 (ja) 2023-07-18
TWI833727B (zh) 2024-03-01
LT3740191T (lt) 2021-08-10
JP2021511317A (ja) 2021-05-06
SI3740191T1 (sl) 2021-09-30
SA520412443B1 (ar) 2022-09-01
EP3740191A1 (en) 2020-11-25
EA202091725A1 (ru) 2020-10-12
TW201932110A (zh) 2019-08-16
US20260027099A1 (en) 2026-01-29
CL2020001895A1 (es) 2020-12-04
EP3915539A1 (en) 2021-12-01
CN111727035A (zh) 2020-09-29
US20210128544A1 (en) 2021-05-06

Similar Documents

Publication Publication Date Title
CO2020009992A2 (es) Composiciones oftálmicas que comprenden bilastina, una beta-ciclodextrina y al menos un agente de gelificación
PE20191650A1 (es) Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue
MA40111B1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
AR108046A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
NO20090723L (no) Kondenserte heterosykliske derivater og fremgangsmater for anvendelse
BR112015029512A2 (pt) derivados de pirazolopirrolidina e seu uso no tratamento de doenças
BR112012012529A2 (pt) composto indol e seu uso farmacêutico
NI201800051A (es) Compuestos de imidazo[4, 5-c]quinolin-2-ona y su uso en eltratamiento de cáncer
BRPI0921097B8 (pt) composto ou seu sal farmaceuticamente aceitável, intermediário do composto, composição farmacêutica e uso do composto
BR112016002651A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, combinação, formulação farmacêutica, métodos para exterminar uma micobactéria e/ou inibir a replicação das micobactérias, e para tratar uma infecção e uma doença, e, uso de um composto
CO2019010029A2 (es) Compuestos de tipo imidazo[4,5-c]quinolin-2-ona deuterados y su uso en el tratamiento del cáncer
CO2019004004A2 (es) Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico
EP2796450A4 (en) 6-AMINOPYRIDIN-3-OL DERIVATIVES OR PHARMACEUTICAL SALTS AND / OR PHARMACEUTICAL COMPOSITION THEREOF AS ACTIVE AGENTS FOR THE PREVENTION OR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES
DOP2013000314A (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib
WO2018234871A3 (en) COMPOSITIONS FOR DRUG DELIVERY AND METHODS OF USE
CO2017005806A2 (es) Nuevos derivados de bencimidazol como agentes antihistamínicos
UY30847A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales
AR089122A1 (es) Formulaciones orales para tratar la sobrecarga de metales
MA33563B1 (fr) 5-(3,4-dichloro-phényl)-n-(2-hydroxy-cyclohexyl)-6-(2,2,2-trifluoro-éthoxy)-nicotinamide et ses sels utilisés comme agents augmentant le cholestérol hdl
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
MX2017009853A (es) Prevencion o tratamiento de enfermedades urinarias o gotosas.
CO2020005939A2 (es) Composiciones acuosas que comprenden bilastina y mometasona
PH12020500246A1 (en) Pharmaceutical compositions
AR064544A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes reductores de la hipertension ocular
BR112019005578A2 (pt) compostos de indazol para uso em lesões no tendão e/ou ligamento

Legal Events

Date Code Title Description
FC Refusal